Free tool
Rare disease stocks
We cover 21 companies grouped under the Rare disease theme. The median market value in the group is $1.06B. Across the group, the median move over the past trading day is +0.03%. 95% of the 20 with a 200-day average trade above it. Price change over the past year runs from +36.8% to +589.9% across the middle 80 percent of the group, with a median of +98.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
21 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| ARGX | argenx SE | $1,047.10 | +20.05% | +24.66% | +47.90% |
| A1RG34.SA | argenx SE | 209.16 BRL | +14.71% | +11.37% | +36.97% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | 166.77 BRL | +12.08% | −0.14% | +4.97% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.84 | +1.17% | +81.55% | +179.08% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.08 | +89.67% | +224.69% | +292.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $31.49 | 0.00% | +36.03% | +55.97% |
| ETON | Eton Pharmaceuticals, Inc. | $62.62 | +34.20% | +285.12% | +262.38% |
| FBRX | Forte Biosciences, Inc. | $76.99 | +0.44% | +226.09% | +589.87% |
| KALV | KalVista Pharmaceuticals Inc | $27.00 | 0.00% | +74.64% | +98.68% |
| OMER | Omeros Corporation | $18.22 | +61.52% | +11.23% | +328.71% |
| ASMB | Assembly Biosciences, Inc. | $35.42 | +38.52% | +4.95% | +36.81% |
| AQST | Aquestive Therapeutics, Inc. | $5.39 | +43.35% | −16.43% | +40.00% |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% |
| CRDL | Cardiol Therapeutics Inc. | $2.14 | +78.33% | +115.29% | +91.07% |
| CRDL.TO | Cardiol Therapeutics Inc. | 2.97 CAD | +74.71% | +118.38% | +90.38% |
| SPRB | Spruce Biosciences, Inc. | $61.48 | +47.79% | −32.22% | +721.93% |
| CPIX | Cumberland Pharmaceuticals Inc. | $8.97 | +69.86% | +125.38% | +163.82% |
| VYNE | VYNE Therapeutics Inc | $28.56 | +3080.40% | +4824.14% | +8660.74% |
| CMMB | Chemomab Therapeutics Ltd. | $2.59 | +81.12% | +44.69% | −25.57% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.33 | +710.86% | +426.12% | +211.51% |
| BSLN.SW | Basilea Pharmaceutica AG | 65.30 CHF | +24.62% | +19.82% | +40.88% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.